While the toxicity against endothelial and other normal cells was not addressed in this study, preliminary results from autologous CD123 CART clinical trial at the City of Hope32 indicated lack of bone marrow or other organ toxicity, and no evidence for capillary leak syndrome. This evidence concerns the gene IL3RA and capillary leak syndrome.